SCHEMBL4266030

SCHEMBL4266030

CSc1ncc2c(Cl)nn(C(C)C)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MERTK Q12866 2/20 0.35
▸ PIM1 P11309 2/20 0.34
▸ TTK P33981 2/20 0.34
▸ PIM2 Q9P1W9 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ LRRK2 Q5S007 3/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ RICTOR Q6R327 1/20 0.32
▸ RPTOR Q8N122 1/20 0.32
▸ MAPKAP1 Q9BPZ7 1/20 0.32
▸ MLST8 Q9BVC4 1/20 0.32
▸ AHR P35869 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258862 0.81 MEN1 (0.39) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL21282841 0.77 KDM4E (0.40) KMT2APIM1KDM4EPDE1C
SCHEMBL22518584 0.76 LRRK2 (0.41) MEN1KMT2ALRRK2
SCHEMBL4256230 0.75 TLR9 (0.35) MEN1KMT2AMERTKKDM4ELMNA
SCHEMBL21087655 0.74 LRRK2 (0.44) MEN1KMT2AMERTKPIM1TTK
SCHEMBL21087750 0.71 LRRK2 (0.43) MEN1KMT2APIM1LMNALRRK2
SCHEMBL27243855 0.71 TSHR (0.43) MERTKPIM1KDM4EMAPTALDH1A1
SCHEMBL27243978 0.71 SMN1; SMN2 (0.40) KDM4ELMNAMAPTLRRK2SMN1; SMN2
SCHEMBL22543688 0.69 USP19 (0.39) MEN1KMT2APIM1TTKPIM2
SCHEMBL31637504 0.68 KMT2A (0.40) MEN1KMT2APIM1TTKPIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029989-A1 SUBSTITUTED PYRAZOLOPYRIMIDINES ADAMS JERRY LEROY 2009-01-29 — — US disclosed
EP-1432714-B1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-08-06 — — EP disclosed
US-20070293489-A1 Substituted Pyrazolopyrimidines ADAMS JERRY 2007-12-20 — — US disclosed
US-7217710-B2 Substituted pyrazolopyrimidines SMITHKLINE BEECHAM CORPORATION (US) 2007-05-15 — — US disclosed
US-20040198751-A1 Pyrazolo-pyrimidine compound; anticancer agents SMITHKLINE BEECHAM CORPORATION 2004-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293489-A1 Substituted Pyrazolopyrimidines DPYD, TPMT, TYMP MEN1 2579/4885KMT2A 2903/4885MERTK 3028/4885
US-20090029989-A1 SUBSTITUTED PYRAZOLOPYRIMIDINES DPYD, TPMT, TYMP MEN1 2579/4885KMT2A 2903/4885MERTK 3028/4885
US-20040198751-A1 Pyrazolo-pyrimidine compound; anticancer agents DPYD, TYMP, TYMS MEN1 1936/4885KMT2A 2059/4885MERTK 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback